Received Jan 22, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | 77KA5 | — |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | UNK | — |
Bexsero-Late 2nd dose/ did not receive 2nd dose; the patient developed a severe rash that lasted 4 or 5 days after the injection; This non-serious case was reported by a other health professional via call center representative and described the occurrence of rash in a 17-year-old male patient who received Men B NVS (Bexsero) (batch number 77KA5, expiry date 30-NOV-2027) for prophylaxis. Co-suspect products included Men B NVS (Bexsero) for prophylaxis. On 27-FEB-2025, the patient received the 1st dose of Bexsero. The patient did not receive the 2nd dose of Bexsero. On an unknown date, an unknown time after receiving Bexsero, the patient experienced rash (Verbatim: the patient developed a severe rash that lasted 4 or 5 days after the injection) and incomplete course of vaccination (Verbatim: Bexsero-Late 2nd dose/ did not receive 2nd dose). The outcome of the rash was resolved (duration 5 days) and the outcome of the incomplete course of vaccination was not applicable. It was unknown if the reporter considered the rash to be related to Bexsero and Bexsero Pre-Filled Syringe Device. It was unknown if the company considered the rash to be related to Bexsero and Bexsero Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 16-JAN-2026 The medical assistant wanted to know whether the patient could receive the 2nd dose of Bexsero now.